stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

China · HKEX: 2196.HK · Market cap: · P/E: · P/S:

Fosun Pharma makes and sells medicines, medical devices and diagnostic tests, and runs hospitals and healthcare services, mainly in China and increasingly around the world.

Fosun Pharma is a Chinese healthcare group that sells the things people need when they get sick: prescription medicines, medical devices, diagnostic tests, and hospital care. It makes most of its money inside China, but it is increasingly a global business too.

The medicines side is the heart of the company. It focuses on areas like cancer, heart and metabolic disease, and infections, and it earns money both from its own branded drugs and from making generic copies of medicines that have lost patent protection. It also sells a wide range of medical devices — things like surgical tools and imaging equipment — and runs a diagnostics business that supplies lab tests to hospitals. On top of that, it owns a network of hospitals and clinics, mostly in China, which gives it a steady, recurring kind of revenue because sick people keep coming through the doors regardless of the economy. The company has a reputation for buying its way into new markets rather than building everything from scratch. It owns stakes in overseas healthcare businesses, including a major stake in the Indian drugmaker Gland Pharma, and it has partnered with foreign firms to bring products to China. That dealmaking muscle comes from its parent, the sprawling conglomerate Fosun International, which has a habit of snapping up assets across industries. But the same strategy that made it big also brings risk: the parent carries a heavy debt load, and worry about that debt has periodically spooked investors in the listed subsidiary.


Fosun Pharma spends heavily on research and development to keep its drug pipeline moving, and its future hinges on whether those new treatments win approval and sell well. It faces tough competition from bigger Chinese drugmakers and global giants, and it has to keep hospitals and health insurers happy on pricing. It is a company that owns a lot of moving parts — pills, devices, tests, and hospital beds — and the job is making them all pull in the same direction.

Saved answer · last researched 15 Nov 2026